Lilly keeps ahead of Blueprint with swift FDA review for selpercatinibEli Lilly says it is eyeing an FDA verdict for RET-positive tumour treatment selpercatinib in the third quarter Share XLilly keeps ahead of Blueprint with swift FDA review for selpercatinibhttps://pharmaphorum.com/news/lilly-keeps-ahead-of-blueprint-with-swift-fda-review-for-selpercatinib/
Relief for Lilly as drug from $8bn Loxo deal clears pivotal trialEli Lilly’s $8 billion acquisition of Loxo Oncology looks like it could pay off, with new data for Share XRelief for Lilly as drug from $8bn Loxo deal clears pivotal trialhttps://pharmaphorum.com/news/relief-for-lilly-as-drug-from-8bn-loxo-deal-clears-pivotal-trial/
ASCO 2018 Preview – what to expect from this year’s conferencepharmaphorum will be presenting live online coverage of this year’s ASCO 2018 conference, the biggest event of the Share XASCO 2018 Preview – what to expect from this year’s conferencehttps://pharmaphorum.com/views-and-analysis/asco-2018-preview-conference/
